The inpatient glucose-lowering drug regimen was dominated by insulin intensive therapy combined with other glucose-lowering drug regimens followed by dual drug combinations and metformin, glycosidase inhibitors, and basal insulin were the most used among T2DM inpatients (Table 2). This evidence concerns the gene INS and type 2 diabetes mellitus.